Antibiotics have been used to treat luminal Crohn’s disease (CD) with variable success. Rifaximin has a favorable safety profile given its limited systemic absorption. Studies suggest clinical improvement in patients with mild-moderate CD treated with rifaximin. Studies evaluating response to rifaximin in moderate-severe luminal CD are limited.